Natural killer T cells in patients with prostatic carcinoma

Area of Science:

• Immunology
• Oncology
• Cell Biology

Background:

• Natural killer T (NKT) cells are emerging as key effector cells in novel immunotherapy strategies.
• NKT cells possess characteristics of both T cells and natural killer cells, are CD1d-dependent, and respond to alpha-galactosylceramide.
• Prostate carcinoma research is exploring new avenues for treatment and understanding disease progression.

Purpose of the Study:

• To investigate the levels of NKT cells in patients with prostate carcinoma.
• To examine the relationship between NKT cell levels and disease progression markers, specifically Prostate-Specific Antigen (PSA).
• To assess the correlation between NKT cells and CD8+ cells in prostate cancer patients.

Main Methods:

• Peripheral blood samples were collected from 54 patients diagnosed with prostatic carcinoma.
• NKT cell counts were measured alongside CD8+ cells and natural killer cells.
• Statistical analysis was performed to compare cell levels between patient groups and to determine correlations.

Main Results:

• Patients with stable PSA levels (androgen withdrawal) exhibited significantly higher NKT cell counts (211.8 cells/microl) compared to those with rising PSA levels (27.0 cells/microl).
• A similar, though less distinct, difference was observed for CD8+ cells between the two groups.
• A strong positive correlation (r = 0.83) was identified between NKT cell and CD8+ cell levels across all patients.

Conclusions:

• NKT cell levels are significantly lower in prostate cancer patients with progressive disease (rising PSA).
• These findings suggest a potentially important regulatory role for NKT cells in the context of prostate carcinoma.
• NKT cells may represent a viable target for future immunotherapeutic interventions in prostate cancer.